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Abstract 
Background  
Laboratory methods for differentiating intravenous substance abuse from medical oral or 
sublingual use are lacking. The disaccharides lactose and sucrose are common excipients in 
both medical preparations and illicit drugs. If substances are abused intravenously, the 
disaccharides are excreted unchanged in urine. This study aimed to evaluate whether urine 
lactose indicates recent intravenous abuse of substances with special reference to 
buprenorphine.  
Methods 
Samples were attained from 21 patients in assessment for opioid maintenance treatment 
(OMT) and from 29 patients already enrolled in OMT. Patients were divided in two groups.  
Group 1 patients reported intravenous abuse of buprenorphine within 48 hours and Group 2 
more than 48 hours since the last injection. The urine samples were assayed for lactose using 
an enzymatic method. To verify intravenous abuse, examination of needle marks and mass 
spectrometric analysis of abused substances were performed. 
Results 
Urine lactose concentration was significantly higher in Group 1 (86 mg/l) than in Group 2 (24 
mg/l). All samples with lactose concentration more than 140 mg/l were given by the Group 1 
patients, who all had recent injection marks. A significant inverse correlation was found 
between the time from last injection and the urine lactose concentration within the 48- hour 
post-injection period.  
Conclusions 
Elevated lactose concentrations in urine could indicate intravenous abuse of substances 
containing lactose. The co-occurrence of higher than 140 mg/l of lactose in urine by means of 
enzymatic assay verified by fresh puncture sites is a potential indicator of recent intravenous 
abuse of buprenorphine. 
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Introduction 
Opioid maintenance treatment (OMT) aims at preventing or significantly reducing illicit 
opioid abuse, drug-related crimes, intravenous substance abuse, and risks associated with 
overdose 1-4. It enables the treatment of opioid dependence and improves patients’ 
psychosocial welfare 1. The need for efficient OMT has been emphasized lately, especially in 
the context of the opioid crisis in the United States 5-7. Yet OMT may be underutilized by 
physicians due to financial reasons, lack of time for more patients, or lack of belief in the 
benefits of OMT 7, 8. The most commonly used OMT medication is either methadone (MET) 
or buprenorphine, the latter being administered in the form of mono-buprenorphine (BPN) or 
the combination preparation buprenorphine-naloxone (BNX) 3, 4. The opioid antagonist 
naloxone in BNX may reduce the risk of diversion and intravenous abuse 4, but it does not 
prevent these actions completely 9-11 among tablet or film users 12. Injection use of 
buprenorphine is the most biologically efficient route of administration in terms of 
bioavailability 11. The most important reasons for injecting BPN/BNX are to treat addiction 
and alleviate withdrawal 9-11. Furthermore, the decision to inject buprenorphine may be 
influenced by cost, as smaller doses can be used in comparison to sublingual dosing 11 
Thus, despite the individual and societal benefits attained with OMT, abuse and diversion of 
OMT drugs still occur 13. In addition, polydrug abuse is a known problem among OMT 
patients, and it appears to be related to insufficient dosage of OMT drugs 14, 15 Through 
existing modern laboratory diagnostics, it is possible to reveal the abuse of illicit drugs, 
allowing appropriate intervention to improve the outcome of OMT and the health of patients 
16, 17.  
Parenteral administration of substances cannot usually be differentiated by ordinary drug 
testing procedures from adequate oral or sublingual administration. However, the OMT 
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medications, as well as several other medicines and also illicit drugs, often contain 
disaccharides as excipients 18. Both the BPN and BNX sublingual tablets contain lactose, and 
some methadone preparations contain sucrose and lactose. When ingested, lactose is 
hydrolysed to its components glucose and galactose, in order to be absorbed intestinally and 
further transferred in to blood circulation 19. If the hydrolysis is impaired, lactose will be 
fermented in to gas and short chain fatty acids in the colon. Therefore, in normal 
circumstances lactose is not excreted in urine as such, but as its metabolite monosaccharides. 
Lactose may be excreted in urine as such in cases of lactose malabsorption 19-21, or when 
prolactin concentrations are elevated, as in pregnancy, breastfeeding or hyperprolactinemia 
22. The levels of lactose in these circumstances vary, and depend on the method and units 
used.  Analysis of disaccharides has been utilized to resolve the route of administration of 
substances with both clinical 23 and post-mortem (PM) 24 urine samples. 
In the present study we apply the simple enzymatic method in an actual clinical setting to the 
analysis of urine lactose in opioid-dependent patients prior to and during OMT. The main aim 
of this study is to assess if the urine lactose might be an indicator of recent intravenous abuse 
of buprenorphine or other licit or illicit substances among opioid dependent patients. To 
verify the laboratory findings, examination of the whole body for injection marks were 
examined concomitantly with the urine sample collection. 
 
Materials and methods 
Patient recruitment 
The opioid-dependent (DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition) patients were either in assessment of the need for OMT or already enrolled in 
OMT at the outpatient clinic for opioid-dependent patients of Helsinki University Central 
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Hospital (HUCH). Fifty-three of the 112 patients (46.1%) gave informed consent for the 
study. One patient later withdrew consent, and in two cases urine samples were not obtained 
from patients who had given informed consent. Thus, 50 patients participated in the study. 
Thirty-seven of these patients also gave a second urine sample at another testing time, as the 
patients are tested in the clinic regularly when in OMT or in evaluation for it. In total, there 
were 87 samples for laboratory analyses. Forty-one urine samples were collected from 21 
patients who were in evaluation for OMT, and 46 samples were collected from 29 patients 
already in OMT. 
The study was approved by the HUCH Ethics Committee for gynecology and obstetrics, 
pediatrics, and psychiatry (record number HUS/1518/2016). The study was conducted in 
accordance with the 1964 Declaration of Helsinki. All study participants were able to read 
and understand the patient information sheet and had signed the informed consent form. The 
participants were free to discontinue their participation in the study at any point. 
 
OMT medications of study patients 
The OMT patients were medicated either with MET or BNX. The BNX medication was 
Suboxone sublingual tablet containing buprenorphine and naloxone in a ratio of 4:1 (Reckitt 
Benckiser Healthcare Ltd., Slough, UK). This sublingual tablet contained also lactose 
monohydrate, mannitol, corn starch, Povidone K 30, citric acid, anhydrous sodium citrate 
magnesium stearate, acesulfame potassium, and natural lemon and lime flavours. The MET 
medication, produced by the HUCH pharmacy, was an oral methadone solution (5 mg/mL) 
containing also methylparahydroxybenzoate. The solution did not contain lactose. 
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Clinical examination and interview 
The patients were examined for both recent and old needle marks, and for this purpose the 
whole body was undressed except for underwear. The analysis of recent and old injection 
marks was carried out according to the WHO guidelines 1, i.e. recent injection marks are 
small and red, and are sometimes inflamed or surrounded by slight bruising. Old injection 
sites are generally not inflamed, but sometimes show pigmentation changes (either lighter or 
darker), and the skin may have atrophied, giving a sunken impression.  
 
Primarily, the patients were asked about recent intravenous abuse of substances, i.e. specific 
drugs injected during the preceding 48 hours and the time in hours since the last intravenous 
injection. In the whole sample, the time intervals since the last intravenous injection were 
grouped as follows: maximally 24 hours, more than 24 hours but maximally 48 hours, more 
than 48 hours but maximally one week, more than one week but maximally one month, or 
more than one month. Patients were divided into two groups according to admitted 
intravenous substance abuse within the last 48 hours. Group 1 consisted of 17 patients (34 
samples) who admitted to intravenous BPN/BNX abuse in maximally 48 hours from 
sampling. The remaining 33 patients who gave 53 samples formed Group 2.   
The patients were also interviewed regarding factors that might interfere with the lactose 
assay, i.e. whether the patient had diabetes, lactose intolerance, or any intestinal illness, or 
whether the patient was pregnant or breastfeeding. These factors did not result in exclusion 
from the study, as this study is currently experimental and the level of lactose concentrations 
did not lead to any consequences for the patients These interfering factors were also 
examined in cases where the N was sufficient for statistical analyses. 
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Urine sample collection for mass spectrometric and enzymatic analyses 
All patient urine samples were collected under supervision (a one-way mirror). Samples were 
collected for the analysis by two mass spectrometric methods, consisting of ultra-high-
performance liquid chromatography/high-resolution quadrupole time-of-flight mass 
spectrometry (UHPLC-HR-QTOFMS)17 and UHPLC-triple quadrupole mass spectrometry 
(UHPLC-MS/MS), as part of the clinical work. These methods enabled both screening and 
quantitative analysis of many illegal and legal psychotropic substances. The quantitative 
performance for buprenorphine, norbuprenorphine, and naloxone was similar to that in a 
method described earlier 25. The same samples were also used for determination of the 
concentrations of lactose. The laboratory analyses were performed blinded both to the clinical 
evaluations and to each other. 
 
Enzymatic assay for determination of lactose in urine 
The urine samples were stored at -20ºC until the analysis of lactose. Prior to analysis, the 
samples were clarified with the use of a 10K centrifugal filter (VWR International, Radnor, 
PA, USA) and diluted 1:1 with water. One sample was discarded from lactose analysis due to 
interfering debris in the sample. Sample volume in lactose assay was 30 µL. 
Lactose was analyzed as previously described 24. The enzymatic R-biopharm Lactose/D-
Galactose kits were purchased from Roche (Darmstadt, Germany). The assay is based on the 
enzymatic hydrolysis of disaccharide to monosaccharides.  In the lactose assay, further 
oxidation of galactose and concomitant reduction of NAD+ to NADH is measured by 
absorbance at 340 nm. The reactions were adapted for a 96-well microplate and the 
measurement was performed on a Multiscan GO-spectrophotometer (ThermoScientific, 
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Waltham, MA, USA). Parallel measurements were performed without the disaccharidase in 
the reaction to correct the effect of possible monosaccharides in urine. The limit of 
quantification (LOQ) for the lactose assay is 15 mg/l as previously described in the validation 
of the method for urine samples 24. For statistical analyses, values less than LOQ for lactose 
was reported as 15 mg/l.  
 
Statistical tools 
The patients were divided into two groups: Group 1 samples (N=34), which were given by 
the patients with admitted intravenous abuse of BPN/BNX during the last 48 hours, and 
Group 2 samples (N=53), which were given by the patients with a longer time interval since 
the last injection prior to sample collection. The normality of the distributions of lactose 
concentration level was analyzed with the Kolmogorov-Smirnov test. Because lactose was 
not normally distributed, non-parametric tests were applied in further statistical analyses. 
Data were indicated as medians, lower quartiles, upper quartiles, and range of the values. 
Two-group comparisons for continuous variables were carried out with the independent 
samples median test and for nominal variables with Fisher’s exact test. The confidence 
interval (CI) was 95%, and the statistical significance level was 0.05. Spearman’s rho (ρ) 
correlations were analyzed for lactose concentrations with different variables. The collected 
data were analyzed by using the IBM SPSS Statistics 25 software. 
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Results 
Descriptive data 
Descriptive data of patients are presented in Table 1. One urine sample was from a patient 
with diabetes, 20 samples were from patients with lactose intolerance, and three samples 
were from patients with an intestinal disorder. None of the patients were pregnant or 
lactating. All Group 1 urine samples were given by patients who were in evaluation of the 
need for OMT, in contrast to no urine samples given by OMT patients (p < 0.01). Therefore 
according to the interview, none of the OMT patients had abused substances intravenously.    
Concentrations of lactose and BPN/BNX 
The distributions of urine concentrations of lactose are presented in Table 2. The median 
lactose concentration in Group 1 differed significantly (p < 0.01) from that in Group 2. In 
addition, the median buprenorphine concentration in Group 1 differed significantly from that 
in Group 2 (p = 0.034). Median norbuprenorphine or naloxone concentrations did not differ 
significantly when Groups 1 and 2 were compared. The boxplots of lactose concentrations in 
Groups 1 and 2 are presented in Figure 1. 
 
Needle marks 
All Group 1 urine samples (N= 34) were given by patients with recent injection marks and 
seven Group 2 samples were given by patients with recent injection marks (p < 0.01). Old 
injection marks were found in 74 samplings from patients; 33 urine samples were given by 
Group 1 patients and 41 urine samples by Group 2 patients (p = 0.013). 
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Correlations between disaccharide concentrations and time from last injection within the 48-
hour post-injection period 
There was a negative correlation between the hours since the last intravenous injection and 
lactose concentration (ρ -0,63, p < 0.01). The correlation is shown in Figure 2. 
 
Correlations between lactose and OMT medication concentrations 
Spearman’s rho correlations were analyzed between lactose concentrations with 
buprenorphine, norbuprenorphine and naloxone concentrations. The correlation of 
buprenorphine with lactose was 0.594 (significant at the 0.01 level) and its metabolite 
norbuprenorphine with lactose was 0.362 (significant at the 0.05 level). There was no 
statistically significant correlation between naloxone and lactose.  
 
Intravenous abuse of other substances  
Four patients reported injecting amphetamine within 48 hours, and two of these patients had 
injected also buprenorphine. Lactose concentration was highest in urine samples given during 
the first post-injection day and when there was concomitant abuse of BPN/BNX (Table 3).  
All of these patients had recent injection marks and the presence of the reported abused 
substances could be verified by the mass spectrometric methods. No traces of amphetamine 
were found from other samples. The study patients did not report intravenous abuse of any 
other substances in the 48-hour post-injection period. 
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Effect of hypolactasia on the analysis method 
The median lactose concentration in Group 2 samples obtained from patients with 
hypolactasia did not differ significantly compared with the samples from patients with no 
hypolactasia (p = 0.451, independent samples median test). The median urine concentrations 
of lactose for patients with hypolactasia and the remaining patients in Group 2 were 26 mg/l 
and 32 mg/l, respectively. The effect of diabetes and intestinal disorders could not be 
evaluated statistically due to the small number of patients with these diseases. Only one 
patient had diabetes accompanied by intestinal disorder (lactose 74 mg/L), and one patient 
had intestinal disorder only, lactose 107 and 71 mg/L at two different sampling times.  
 
Discussion and conclusions  
 
This study shows that the urine lactose is a potential indicator of recent intravenous abuse of 
BNX among opioid dependent patients. The median urine lactose concentration was 
significantly higher in Group 1 (86 mg/l) than in Group 2 patients (24 mg/l). All urine 
samples (N = 12) with lactose concentration more than 140 mg/l were given by the Group 1 
patients.  In addition, the lactose concentration correlated significantly with the 
concentrations of buprenorphine and norbuprenorphine. The lactose concentrations decreased 
significantly during the 48-hour post-injection period. Figure 2 shows that the lactose 
concentrations are highest in the first hours after admitted intravenous injection, decreasing 
rapidly after 7-10 hours. It appears that most of the lactose is secreted in urine within the first 
24 hours.  
Intravenous substance abuse is often studied by surveys and also by needle mark 
examinations. In Finland, the most common intravenously abused illicit drugs are 
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amphetamine and buprenorphine 26. Intravenous substance abuse predisposes the patients to 
infectious diseases and other somatic complications, causes serious poisonings 27-29 and 
impairs the benefits of OMT. To find a diagnostic solution to detect intravenous abuse, 
Jungen et al. 23 introduced a liquid chromatography - photodiode array detection (LC-DAD) 
method to detect urine disaccharides and, more recently, an LC-MS/MS method for the same 
purpose 30. While these methods are specific and measure the disaccharides directly, the 
enzymatic method used in the present study is cost-effective, easy to perform, and readily 
adapted to every laboratory, as it requires only basic laboratory equipments. The new 
diagnostic tool may for its part improve the reported underuse of BPN 5, 7. Although the focus 
here is mainly on BPN/BNX, the assay can be applied to reveal other intravenously abused 
substances if the excipients include lactose. For example, methadone hydrochloride tablets 
(Mallinckrodt Inc.) contain lactose monohydrate. Thus, the urine lactose analyses can be 
useful also in revealing the intravenous abuse of MET in other clinical settings. This is 
important due to the increasing amount of reported methadone diversion 31. Furthermore, 
opioid dependence is a chronic and relapsing disorder 3 and even after a long abstinence 
intravenous abuse of substances may occur.  
This study reports four samples from patients who had admitted to recent injecting of 
amphetamine. Two of these patients had injected also BPN/BNX. The highest level of lactose 
was observed for a patient with intravenous co-abuse of amphetamine and BPN/BPX in the 
sample provided during the first post-injection day. On the other hand, the lowest 
concentration of lactose was found in the urine sample of a patient who had abused only 
amphetamine nearly two days earlier. This finding is in line with the fact that amphetamine 
preparations may contain lactose in different amounts to dilute or to add bulk to the abused 
substance 18.  
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In our previous study, we applied an enzymatic method to detect the disaccharides lactose 
and sucrose mainly in PM urine samples 24, and a correlation was found between lactose 
concentration and the presence of BPN or BNX. A similar enzymatic method had been 
previously used in the assessment of intestinal permeability of patients with hypolactasia, 
celiac disease, or inflammatory bowel disorders 20, 21 Although the enzymatic method itself is 
feasible and cost-effective, a major limitation of our previous study was the lack of detailed 
information concerning the subjects studied, as we had access to laboratory results only, and 
not to autopsy findings or previous health records. Moreover, clinical samples were tested 
only to evaluate the effect of PM changes on sample material. In this study, hypolactasia did 
not appear to elevate lactose concentrations significantly, although it is likely that the patients 
suffering from hypolactasia avoid lactose-containing food and drinks due to the unpleasant 
symptoms. Therefore, it is unlikely that disturbing amounts of lactose would be present in 
urine due to impaired intestinal hydrolysis, if only small amounts or none is ingested. 
Information on intestinal disorders and hypolactasia was based on patient interview and not 
confirmed by laboratory methods, which is one limitation of this study. The effect of neither 
pregnancy nor lactation on urine lactose concentrations could be assessed in this study, as 
there were no patients in these groups. These factors require additional research with patient 
samples from gastroenterological and obstetric fields.  
One purpose of OMT is reducing intravenous abuse of substances. This decreases the risk of 
infectious diseases, poisonings, and severe somatic complications. Medications intended for 
oral use but crushed and diluted in water and then injected as well as injected illicit drugs, 
like heroin, cocaine, and methadone, commonly contain microscopic insoluble material, such 
as talc, cellulose, crospovidone, and starch, which can induce even fatal pulmonary vascular 
injury 32, 33. Prevention of such complications by all possible means is crucial.  
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In addition to the limitations discussed before, the numbers of urine samples and study 
patients were relatively small, giving rise to possible statistical type I and II errors. Moreover, 
this study cannot definitely state which BPN/BNX preparations were abused by the patients. 
Regarding new BNX medications, the rapidly dissolving sublingual tablet containing 
sucralose is not yet officially available in Finland. Furthermore, it is possible that in Group 2 
there were some patients that had intravenously abused substances, but were not willing to 
admit it. 
In conclusion, enzymatic detection of lactose in urine can reveal intravenous abuse of some 
BPN/BNX preparations. In addition to the laboratory analysis, information acquired from 
patients and examination of needle marks are always needed in clinical practice with patients 
suspected of intravenous drug abuse. 
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Figure 1. Boxplots of lactose concentrations in Groups 1 (intravenous abuse of BPN/BNX 
during the last 48 hours) and 2 (no intravenous abuse within 48 hours). 
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Figure 2. Lactose concentrations in cases with intravenous BPN/BNX abuse relative to time 
from injection within the 48-hour post-injection period. 
  
  
This article is protected by copyright. All rights reserved. 
Table 1. Descriptive patient and sample data. 
 All Group 1 Group 2 
Patients 
Gender (male/female) 
50 
31/19 
17 
14/3 
33 
17/16 
Age, median (years) 33 31 34 
Age, range (years) 
Hypolactasia 
21-49 
13 
23-37 
3 
21-49 
10 
Diabetes 1 0 1 
Intestinal disorder 2 0 2 
Admitted recent i.v. abuse (≤48 h) 19 17 2 
 BPN or BNX /+amphetamine  
 amphetamine  
15/2 
2 
15/2 
0 
0 
2 
    
Samples 87 34 53 
Hypolactasia 20 6 14 
Diabetes 1 0 1 
Intestinal disorder 3 0 3 
Admitted recent (≤48 h) i.v. abuse 36 34 2 
 BPN or BNX abuse/ + amphetamine 
 amphetamine abuse 
32/2 
2 
32/2 
0 
0 
2 
BNX; buprenorphine-naloxone 
BPN; buprenorphine 
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Table 2. Urine concentrations of lactose between intravenous BPN/BNX abusers and other 
patients  
  Lactose (mg/l) 
All samples Median 
Range 
33 
<15-439 
 Lower quartile 19 
 Upper quartile 91 
 N 86 
Group 1, recent (≤ 48 hours)  i.v. abuse of 
BPN/BNX 
Median 
Range 
86 
<15-439 
 Lower quartile 32 
 Upper quartile 176 
 N 34 
Group 2,  No recent i.v. abuse of BPN/BNX  Median 
Range 
24 
<15-140 
 Lower quartile <15 
 Upper quartile 49 
 N 52 
BNX; buprenorphine-naloxone 
BPN; buprenorphine 
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Table 3. Lactose concentrations in samples with intravenous amphetamine abuse. 
Patient Admitted substance abuse 
Amphetamine/Buprenorphine 
Lactose 
mg/l 
Hours since last 
intravenous injection 
1 yes/yes 163 23 
2 yes/yes 44 20 
3 yes/no 25 31 
4 yes/no <15 46 
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